Notably, the current study demonstrated that PRV combination treatment at all doses significantly decreased Ang II, ET-1, and TGF-β serum levels demonstrating that the apitherapy combination may modulate hypertension-related factors. The gene discussed is EDN1; the disease is hypertensive disorder.